New Data on Four Bristol-Myers Squibb Compounds to be Presented at AASLD 2009

PRINCETON, New Jersey, October 1 /PRNewswire/ --

New data on four Bristol-Myers Squibb Company (NYSE: BMY) compounds will be presented at the 60th annual meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston from October 30 to November 3.

Data will be presented on BARACLUDE(R) (entecavir) in patients with chronic hepatitis B, and on two compounds in early clinical development for the treatment of hepatitis C -- BMS-650032, an NS3 inhibitor, and PEG-Interferon lambda, a novel type 3 interferon. The presentation of data on BMS-650032 will mark the first public disclosure of information about this investigational compound. Data will also be presented on the investigational compound brivanib, the first selective dual inhibitor of fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF) signaling, which is in Phase 3 development for the treatment of hepatocellular carcinoma.

"The data on Bristol-Myers Squibb compounds that will be presented at AASLD demonstrate the breadth of our research and development portfolio and support the company's goal of developing innovative medicines for patients with various diseases of the liver," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, Research and Development, Bristol-Myers Squibb. "Our established expertise in viral hepatitis and oncology uniquely position Bristol-Myers Squibb to be at the forefront of delivering innovation in the treatment of multiple types and stages of liver disease. We are proud to be releasing new data on our significant portfolio of assets."

BARACLUDE, BMS-650032 and brivanib were discovered by Bristol-Myers Squibb Research and Development. BMS-650032 is Bristol-Myers Squibb's second small molecule under development for the treatment of hepatitis C, joining BMS-790052, a first-in-class investigational NS5A inhibitor of the hepatitis C virus.

PEG-Interferon lambda was discovered by ZymoGenetics, Inc. Bristol-Myers Squibb and ZymoGenetics announced a global collaboration for PEG-Interferon lambda and its related development program earlier this year.

The times, titles and lead authors of the data presentations are as follows:

    
    Date/Time       Presentation Title        Lead Author
    ---------       ------------------        -----------
    Hepatitis B
    October 31,     Efficacy and Safety of    Y. Liaw
    2:00 - 8:00     Entecavir versus          Chang Gung
    p.m. EDT        Adefovir in Chronic       Memorial Hospital,
                    Hepatitis B Patients      Chang Gung
                    with Evidence of          University
                    Hepatic                   College of Medicine
                    Decompensation            Taipei, Taiwan
                    (Abstract #422)          
                                          
    Hepatitis C
    November 3,     Safety, Tolerability,     C. Pasquinelli
    12:00 - 12:15   Pharmacokinetics and      Bristol-Myers Squibb
    p.m. EST        Antiviral Activity      
                    following Single- and  
                    Multiple-Dose
                    Administration of
                    BMS-650032, a Novel
                    HCV NS3 Inhibitor, in
                    Subjects with Chronic
                    Genotype 1 HCV
                    Infection (Abstract
                    #225)

    November  3,    Genotypic and             F. McPhee
    8:00 a.m. -     Phenotypic Analysis       Bristol-Myers Squibb
    1:00 p.m. EST   of Samples from        
                    HCV-Infected Subjects
                    Treated with
                    BMS-650032 in a
                    Single Ascending Dose
                    Study (Abstract #1607)

    November 3,     A Phase 1b                A.J. Muir
    8:00 a.m. -     Dose-Ranging Study of     Duke University
    1:00 p.m. EST   4 Weeks of                School of Medicine
                    PEG-Interferon (IFN)      Durham, North Carolina
                    Lambda (PEG-rIL-29)    
                    in Combination with    
                    Ribavirin (RBV) in      
                    Patients with Chronic  
                    Genotype 1 Hepatitis
                    C Virus (HCV)
                    Infection (Abstract
                    #1591)
    Hepatocellular Carcinoma
    November 3,     Time-to-Progression       R. Finn
    8:00 a.m. -     Analysis of               UCLA Los Angeles, CA
    1:00 p.m. EST   Second-line Treatment  
                    with Brivanib in        
                    Patients with
                    Unresectable, Locally
                    Advanced, or
                    Metastatic
                    Hepatocellular
                    Carcinoma (Abstract
                    #1683)
    November 3,     Cell-dependent            J. Park
    8:00 a.m. -     Response of               National Cancer Center
    1:00 p.m. EST   BMS-582664 (Brivanib)     Goyang, South Korea
                    in Hepatocellular      
                    Carcinoma Cells: Gene  
                    Expression Profiling    
                    Study (Abstract #1668)  

About BARACLUDE(R)

Discovered at Bristol-Myers Squibb, BARACLUDE(R) is a nucleoside analogue indicated for use in adults with chronic hepatitis B infection with compensated liver disease, evidence of active viral replication, and either evidence of persistent elevations of the blood levels of aminotransferases - a marker for liver disease - or active liver disease as determined by biopsy. BARACLUDE (entecavir) has been approved in more than 86 countries and regions around the world.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

BARACLUDE(R) (entecavir) is a registered trademark of Bristol-Myers Squibb Company.

Media, Annie Simond, office: +33-1-58-83-65-66, annie.simond@bms.com, or Investors, John Elicker, +1-609-252-4611, john.elicker@bms.com